NCT02865785

Effect of Intralipid Infusion in Patients With Recurrent Implantation Failure

Effect of Intralipid Infusion in Patients With Recurrent Implantation Failure (A Randomized Controlled Trial)

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 320 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: Female
• Age: 20 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

The aim of present study is to evaluate the effect of intralipid 20% infusion, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test on clinical pregnancy rates in women with unexplained recurrent implantation failure.

Detailed description

The study will include 300 women with unexplained recurrent implantation failure undergoing IVF/ICSI cycle. Randomization: Patients fulfilling the inclusion criteria will be randomized to two groups. Study Group: This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20%, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test. Control Group: This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test. Random allocation sequence generation: A computer generated list via MedCalc ® Software, version 13.2.2 will be used, assigning each participant number to either study groups. Allocation Concealment: Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the assigned group. These papers will be placed in a folded sheet of aluminum foil fitted inside the envelope. Effort will be taken to assure absence of any detectable differences in size or weight between intervention and control envelopes. Envelopes will be chosen to be opaque and lined inside with carbon paper. Envelopes will be opened sequentially only after writing the subject's tracking information on the envelope so that the carbon paper served as an audit trail. Blinding: Both drug with active ingredient and placebo will be provided by the hospital pharmacy in identical sealed opaque containers, equal in weight, similar in appearance, and tamper-proof. The drug with the active ingredient containers will be labeled either Group A or Group B by the head pharmacist and the assignment kept secret to be revealed after the end of the study. Drugs will be administered to patients by a sealed opaque infusion drip. An endometrial biopsy (Wallach endocell sampler ® ) will be taken during the luteal phase of the menstrual cycle and put in formalin. The biopsy will be embedded in paraffin, cut into sections and immunohistochemistry will be used to identify uNK cells using an antibody to CD56 and CD16 (NCL-CD56-16; Novacastra ® ). A cut-off of normality of 5% uNK cell density will be used. IVF/ICSI cycle will be done using the standard LLP in both groups. primary outcome will be Live birth rate. secondary outcomes will be biochemical and clinical pregnancy rates.

Conditions

• Subfertility

Interventions

Type	Name	Description
DRUG	Intralipid 20%	intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
DRUG	Placebo	saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.

Timeline

• Start date: 2016-07-01
• Primary completion: 2017-07-01
• Completion: 2017-08-01
• First posted: 2016-08-12
• Last updated: 2016-08-12

Locations

1 site across 1 country: Egypt